On therapeutic approaches to some special types of acne.
The aim of the present study was to evaluate different treatment schedules in some different types of acne using a quantitative counting technique. Systemic treatment with erythromycine 0.5 g daily and topical treatment with clindamycin phosphate solution 1% was found to be optimal from the efficacy/side effect ratio. The combined treatment was tried in heat-provoked and cosmetic acne with favourable results. Doubling of erythromycine dosage could not prevent premenstrual exacerbation of acne. Diazepam 4 mg daily for two weeks followed by an antihistamine in addition to erythromycine 0.5 g daily gave relatively good results in female patients with acne excorié. In acne coexisting with pronounced seborrhoic dermatitis of the face the addition of hydrocortisone cream 1% was of benefit, although Roaccutane may here be the drug of choice. In female postpubertal acne, the effect of cyproteronacetate-etynilestradiol (Diane) was not superior to treatment with erythromycine 0.5 g daily. By treating special subtypes differently, one could be able to improve the results of acne therapy.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001585:Benzoyl Peroxide / Q000627:therapeutic use; D002981:Clindamycin / Q000031:analogs & derivatives / Q000627:therapeutic use; D003534:Cyproterone / Q000627:therapeutic use; D017373:Cyproterone Acetate; D003975:Diazepam / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006854:Hydrocortisone; D008297:Male; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D014212:Tretinoin / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000726:Androgen Antagonists; D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D002981:Clindamycin; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D014212:Tretinoin; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D004917:Erythromycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D003534:Cyproterone; C007084:clindamycin phosphate; D013752:Tetracycline; D013420:Sulfamethoxazole; D003975:Diazepam; D001585:Benzoyl Peroxide; D006854:Hydrocortisone